The efficacy of anti‐programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma

The efficacy of anti‐programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma

Abstract Background Anti‐programmed cell death protein 1 (PD‐1) antibodies are a standard treatment for metastatic melanoma patients. However, the understanding of the efficacy of anti‐PD‐1 for acral melanoma (AM) and mucosal melanoma (MM) is limited as these subtypes are relatively rare compared to...

Full description

Bibliographic Details
Main Authors: Dai Ogata, Lauren E. Haydu, Isabella C. Glitza, Sapna P. Patel, Hussein A. Tawbi, Jennifer L. McQuade, Adi Diab, Suhendan Ekmekcioglu, Michael K. Wong, Michael A. Davies, Rodabe N. Amaria
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:Cancer Medicine
Subjects:
acral melanoma
anti‐PD‐1
malignant melanoma
mucosal melanoma
Online Access:https://doi.org/10.1002/cam4.3781

Internet

https://doi.org/10.1002/cam4.3781

Similar Items